The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
Open accessAbstract
Purpose: Third-generation aromatase inhibitors have been widely used in postmenopausal women for the adjuvant treatment of hormone receptor–positive breast cancer. As aromatase inhibitors work by inhibiting the conversion of androgens to estrogens in adipose tissue, we hypothesized that anastrozole may be more effective in women with a high body mass index (BMI). Patients and Methods: The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized clinical trial in which postmenopausal women with early-stage breast cancer were randomly assigned to receive oral daily anastrozole (1 mg) alone, tamoxifen (20 mg) alone, or the combination in a double-blind fashion. Analyses were based on the 100-month median follow-up for women with hormone receptor–positive breast cancers (estrogen [ER] and/or progesterone [PgR] positive). Here, we investigate the impact of BMI on recurrence and the relative benefit of anastrozole versus tamoxifen according to baseline BMI. Results: Overall, women with a high BMI (BMI > 35 kg/m 2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m 2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; P heterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; P heterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Self-citationReeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Source of Estrogen Production in Postmenopausal Women1
GRODIN, J. M., SIITERI, P. K., & MACDONALD, P. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-2-207 · Cited by 959
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Coates, A. S., Keshaviah, A., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8617 · Cited by 910
Self-citationCoombes, R., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., Jassem, J., Van de Velde, C., Delozier, T., Alvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 907
Self-citationThe ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Weight Loss in Breast Cancer Patient Management
Chlebowski, R. T., Aiello, E. J., & McTiernan, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.1128 · Cited by 623
Adipose tissue as a source of hormones
Siiteri, P. K. (1987) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/45.1.277 · Cited by 599
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Morimoto, L. M., White, E., Chen, Z., Chlebowski, R. T., Hays, J., Kuller, L., Lopez, A. M., Manson, J., Margolis, K. L., Muti, P. C., et al. (2002) · Cancer Causes & Control · doi:10.1023/a:1020239211145 · Cited by 569
MacDonald, P. C., Edman, C. D., Hemsell, D. L., Porter, J. C., & Siiteri, P. K. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90287-9 · Cited by 440
FOLSOM, A. R., KAYE, S. A., PRINEAS, R. J., POTTER, J. D., GAPSTUR, S. M., & WALLACE, R. B. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115570 · Cited by 331
Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer
Loi, S., Milne, R. L., Friedlander, M. L., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Phillips, K.-A. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0042 · Cited by 319
Caan, B. J., Kwan, M. L., Hartzell, G., Castillo, A., Slattery, M. L., Sternfeld, B., & Weltzien, E. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9203-0 · Cited by 246
Dignam, J. J. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg060 · Cited by 223
Is obesity an independent prognosis factor in woman breast cancer?
Majed, B., Moreau, T., Senouci, K., Salmon, R. J., Fourquet, A., & Asselain, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9785-3 · Cited by 220
Edman, C. D., & MacDonald, P. C. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90288-0 · Cited by 205
DAVIES, C. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(04)00121-5 · Cited by 170
Origin of serum estradiol in postmenopausal women.
Hl, J., Im, S., Am, F., & Lagasse, L. D. (1982) · PubMed · Cited by 162
Lippman, M. E., Krueger, K. A., Eckert, S., Sashegyi, A. I., Walls, E. L., Jamal, S. A., Cauley, J. A., & Cummings, S. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3111 · Cited by 144
Identification of the estrogen product of extraglandular aromatization of plasma androstenedione
Edman, C. D., Aiman, E. J., Porter, J. C., & MacDonald, P. C. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90286-7 · Cited by 82
Jain, M. G., & Miller, A. B. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005798124538 · Cited by 52
Monnier, A. (2006) · The Breast · doi:10.1016/j.breast.2006.01.004 · Cited by 17
Cited by
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationChan, D. S. M., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., Navarro Rosenblatt, D., Thune, I., Vieira, R., & Norat, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu042 · Cited by 1,165
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
Morris, P. G., Hudis, C. A., Giri, D., Morrow, M., Falcone, D. J., Zhou, X. K., Du, B., Brogi, E., Crawford, C. B., Kopelovich, L., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0110 · Cited by 465
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Jiralerspong, S., & Goodwin, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4480 · Cited by 405
Metadata
- Authors
- Sestak, I., Distler, W., Forbes, J. F., Dowsett, M., Howell, A., & Cuzick, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-07-20
- Volume
- 28
- Issue
- 21
- Pages
- 3411-3415
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115138807
- Cited by
- 311
- References
- 29
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.